Trevi Therapeutics Stock Number Of Shares Shorted
| TRVI Stock | USD 4.36 0.24 5.83% |
Trevi Therapeutics fundamentals help investors to digest information that contributes to Trevi Therapeutics' financial success or failures. It also enables traders to predict the movement of Trevi Stock. The fundamental analysis module provides a way to measure Trevi Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Trevi Therapeutics stock.
Trevi | Number Of Shares Shorted |
Trevi Therapeutics Company Number Of Shares Shorted Analysis
Trevi Therapeutics' Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
Current Trevi Therapeutics Number Of Shares Shorted | 4.66 M |
Most of Trevi Therapeutics' fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Trevi Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Trevi Number Of Shares Shorted Driver Correlations
Understanding the fundamental principles of building solid financial models for Trevi Therapeutics is extremely important. It helps to project a fair market value of Trevi Stock properly, considering its historical fundamentals such as Number Of Shares Shorted. Since Trevi Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Trevi Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Trevi Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, Trevi Therapeutics has 4.66 M of outstending shares currently sold short by investors. This is 45.54% higher than that of the Pharmaceuticals sector and 8.66% lower than that of the Health Care industry. The number of shares shorted for all United States stocks is 1.05% higher than that of the company.
Trevi Number Of Shares Shorted Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Trevi Therapeutics' direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Trevi Therapeutics could also be used in its relative valuation, which is a method of valuing Trevi Therapeutics by comparing valuation metrics of similar companies.Trevi Therapeutics is currently under evaluation in number of shares shorted category among its peers.
Trevi Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Trevi Therapeutics from analyzing Trevi Therapeutics' financial statements. These drivers represent accounts that assess Trevi Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Trevi Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 43.7M | 17.9M | 124.6M | 132.7M | 119.4M | 63.2M | |
| Enterprise Value | 12.9M | (4.3M) | 121.2M | 101.6M | 116.9M | 64.4M |
Trevi Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Trevi Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Trevi Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Trevi Fundamentals
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.37 | ||||
| Current Valuation | 303.81 M | ||||
| Shares Outstanding | 89.37 M | ||||
| Shares Owned By Insiders | 1.00 % | ||||
| Shares Owned By Institutions | 70.42 % | ||||
| Number Of Shares Shorted | 4.66 M | ||||
| Price To Book | 6.24 X | ||||
| EBITDA | (33.8 M) | ||||
| Net Income | (29.07 M) | ||||
| Cash And Equivalents | 77.86 M | ||||
| Cash Per Share | 1.82 X | ||||
| Total Debt | 1.34 M | ||||
| Debt To Equity | 0.21 % | ||||
| Current Ratio | 5.18 X | ||||
| Book Value Per Share | 0.78 X | ||||
| Cash Flow From Operations | (31.71 M) | ||||
| Short Ratio | 1.30 X | ||||
| Earnings Per Share | (0.44) X | ||||
| Target Price | 9.81 | ||||
| Number Of Employees | 27 | ||||
| Beta | 1.01 | ||||
| Market Capitalization | 368.19 M |